



**Proteomics International**

LABORATORIES LTD

**ASX Release**  
**14 December 2022**

**ASX code: PIQ**

## **UK's National Institute for Health and Care Excellence (NICE) publishes Medtech Innovation Briefing on PromarkerD**

- **PromarkerD selected for National Institute for Health and Care Excellence (NICE) briefing to UK clinicians, managers and procurement professionals**
- **Medtech Innovation Briefing, known as NICE advice, reports that PromarkerD is effective at predicting renal function decline in people with type 2 diabetes**
- **Independent experts appointed by NICE advised that the technology is novel and could lead to a decrease in the number of people developing end-stage renal disease, reducing hospitalisation and the need for dialysis**
- **Outcome is a major milestone towards reimbursement and the broad adoption of PromarkerD in the UK - Company will now target the inclusion of the test in the NICE guidelines**
- **There are approximately 4.0 million adults living with diabetes in the UK**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to announce the publication of a Medtech Innovation Briefing (MIB) on the PromarkerD predictive test for diabetic kidney disease by the National Institute for Health and Care Excellence (NICE) in the United Kingdom. NICE is an independent organisation established by the UK Government to provide national guidance and advice to it on medical treatments.

Medtech Innovation Briefings are commissioned by the National Health Service (NHS) in the UK. Known as NICE advice, they are designed to increase awareness of new technologies for planning and commissioning new innovation in the UK healthcare industry.

The NICE advice, aimed at clinicians, managers and procurement professionals in the UK, reports that PromarkerD is effective at predicting renal function decline in people with type 2 diabetes.

There is a rigorous selection process for inclusion in the NICE advice process, taking into account the potential benefits of a technology, its regulatory status, clinical evidence and more. There have been only 29 Medtech Innovation Briefings published this year.

In assessing the evidence for PromarkerD, independent experts appointed by NICE advised that the technology is novel and is expected to be used in addition to standard care tests. They said that PromarkerD may allow the identification of high-risk patients earlier, which would alter the treatment they receive. This could lead to a decrease in the number of people developing end-stage renal disease, reducing hospitalisation and the need for dialysis.

Proteomics International Managing Director Dr Richard Lipscombe said the briefing was a major milestone for PromarkerD. *"Selection of the test as an innovative technology worthy of NICE advice is an important step towards future recommendation for clinical use of PromarkerD in the UK."*

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

*“The Medtech Innovation Briefing provides objective information to help doctors make the best clinical decisions for their patients. The NICE advice supports the reimbursement process and broader adoption of PromarkerD in the UK, and its publication enables us to pursue inclusion of PromarkerD in the NICE Guidelines and to engage with the NHS Supply Chain Tender process.”* The Company will provide timelines for these processes when known.

These Medtech briefings are also looked at by the broader healthcare industry in the UK and will allow for positive engagement with private healthcare providers beyond the NHS. The UK represents a significant market opportunity for PromarkerD with approximately 4.0 million adults (8.2%) living with diabetes, and an additional 3.0 million with prediabetes<sup>1</sup>. The PromarkerD test is already registered for use with the UK Medicines & Healthcare products Regulatory Agency.

The full Medtech Innovation Briefing for PromarkerD (MIB 312) can be found at the National Institute for Health and Care Excellence website<sup>2</sup>.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

#### **About PromarkerD ([www.PromarkerD.com](http://www.PromarkerD.com))**

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique ‘fingerprint’ of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: [www.PromarkerD.com/product](http://www.PromarkerD.com/product)

#### **About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

#### **For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Investor Relations & Corporate Advisor  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@eurozhartleys.com](mailto:kmoss@eurozhartleys.com)

<sup>1</sup> International Diabetes Federation Diabetes Atlas 10<sup>th</sup> edition, 2021

<sup>2</sup> [www.nice.org.uk/guidance/published](http://www.nice.org.uk/guidance/published)